Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression
- Reiner, Martin F. Center for Molecular Cardiology, Laboratory for Platelet Research, University of Zurich, Schlieren, Switzerland - Laboratory of Aging and Stroke, University of Zurich, Schlieren, Switzerland - Department of Internal Medicine, Cantonal Hospital of Baden, Switzerland
- Akhmedov, Alexander Laboratory for Endothelial Research, University of Zurich, Schlieren, Switzerland
- Stivala, Simona Center for Molecular Cardiology, Laboratory for Platelet Research, University of Zurich, Schlieren, Switzerland - Department of Internal Medicine, Cantonal Hospital of Baden, Switzerland
- Keller, Stephan Laboratory of Aging and Stroke, University of Zurich, Schlieren, Switzerland - Laboratory for Endothelial Research, University of Zurich, Schlieren, Switzerland
- Gaul, Daniel S. Laboratory for Atherosclerosis Research, University of Zurich, Schlieren, Switzerland
- Bonetti, Nicole R. Center for Molecular Cardiology, Laboratory for Platelet Research, University of Zurich, Schlieren, Switzerland - Laboratory of Aging and Stroke, University of Zurich, Schlieren, Switzerland
- Savarese, Gianluigi Division of Cardiology, Department of Medicine, Karolinska Institute, Solna (MedS), Stockholm, Sweden
- Glanzmann, Martina Laboratory for Endothelial Research, University of Zurich, Schlieren, Switzerland
- Zhu, Cuicui Department of Medicine/Physiology, University of Fribourg, Switzerland
- Ruf, Wolfram Center for Thrombosis and Hemostasis, University Medical Center, Johannes Gutenberg-University Mainz, Germany
- Yang, Zhihong Department of Medicine/Physiology, University of Fribourg, Switzerland
- Matter, Christian M. Laboratory for Atherosclerosis Research, University of Zurich, Schlieren, Switzerland
- Lüscher, Thomas F. Laboratory for Endothelial Research, University of Zurich, Schlieren, Switzerland - Department of Cardiology, University Heart Center, University Hospital Zurich, Switzerland
- Camici, Giovanni G. Center for Molecular Cardiology, Laboratory for Platelet Research, University of Zurich, Schlieren, Switzerland - Laboratory of Aging and Stroke, University of Zurich, Schlieren, Switzerland - Department of Cardiology, University Heart Center, University Hospital Zurich, Switzerland
- Beer, Juerg H. Center for Molecular Cardiology, Laboratory for Platelet Research, University of Zurich, Schlieren, Switzerland - Department of Internal Medicine, Cantonal Hospital of Baden, Switzerland
-
01.01.2017
Published in:
- Cardiovascular Research. - 2017, vol. 113, no. 1, p. 61–69
English
The P2Y12 antagonist ticagrelor reduces mortality in patients with acute coronary syndrome (ACS), compared with clopidogrel, and the mechanisms underlying this effect are not clearly understood. Arterial thrombosis is the key event in ACS; however, direct vascular effects of either ticagrelor or clopidogrel with focus on arterial thrombosis and its key trigger tissue factor have not been previously investigated.Methods and results: Human aortic endothelial cells were treated with ticagrelor or clopidogrel active metabolite (CAM) and stimulated with tumour necrosis factor-alpha (TNF-α); effects on procoagulant tissue factor (TF) expression and activity, its counter-player TF pathway inhibitor (TFPI) and the underlying mechanisms were determined. Further, arterial thrombosis by photochemical injury of the common carotid artery, and TF expression in the murine endothelium were examined in C57BL/6 mice treated with ticagrelor or clopidogrel. Ticagrelor, but not CAM, reduced TNF-α-induced TF expression via proteasomal degradation and TF activity, independently of the P2Y12 receptor and the equilibrative nucleoside transporter 1 (ENT1), an additional target of ticagrelor. In C57BL/6 mice, ticagrelor prolonged time to arterial occlusion, compared with clopidogrel, despite comparable antiplatelet effects. In line with our in vitro results, ticagrelor, but not clopidogrel, reduced TF expression in the endothelium of murine arteries.Conclusion: Ticagrelor, unlike clopidogrel, exhibits endothelial-specific antithrombotic properties and blunts arterial thrombus formation. The additional antithrombotic properties displayed by ticagrelor may explain its greater efficacy in reducing thrombotic events in clinical trials. These findings may provide the basis for new indications for ticagrelor.
- Faculty
- Faculté des sciences et de médecine
- Department
- Département de Médecine
- Language
-
- English
- Classification
- Biological sciences
- License
- License undefined
- Identifiers
-
- RERO DOC 288717
- DOI 10.1093/cvr/cvw233
- Persistent URL
- https://folia.unifr.ch/unifr/documents/305563
Other files
Statistics
Document views: 38
File downloads:
- yan_tnc.pdf: 72
- yan_tnc_sm.pdf: 60